PRINCETON, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, today announced that it has rescheduled the release of the Company’s first quarter 2024 financial results to Monday, May 6, 2024. In

PRINCETON, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed its acquisition of Acclarent, Inc. , a pioneer in ear, nose and throat (ENT) surgical

Novel system features flexible tip to deliver flowable version of the Urinary Bladder Matrix (UBM) technology PRINCETON, N.J., March 11, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (Nasdaq:IART), today announced MicroMatrix® Flex is now available commercially in the U.S.

PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Reported revenues were $397.0 million, representing a decrease of 0.2% on a

Jan De Witte to retire as CEO by the end of 2024 Stuart Essig appointed executive chairman of the Board PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (“Integra” or “the Company”) (NASDAQ: IART), a leading global medical technology company, today

PRINCETON, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, prior to the market open. In conjunction with

PRINCETON, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, announced today that Jan De Witte, president and chief executive officer will present at the 42nd Annual J.P.

The acquisition will become part of Integra’s Codman Specialty Surgical (CSS) division. The ear, nose and throat (ENT) category is a key area of strategic interest and highly complementary to the neurosurgery segment. Provides a unique opportunity to build scale and capture a leadership position in

PRINCETON, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (Nasdaq: IART), a leading global medical technology company, today announced that Jeff Graves, Ph.D., president and chief executive officer of 3D Systems Corporation, was appointed to the company’s board

PRINCETON, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2023. Third Quarter 2023 Highlights Third quarter revenues of $382.4